The global tuberculosis (TB) diagnostics market size was estimated to be USD 2.84 billion in 2023 and is expected to reach at USD 6.3 billion by 2033 with a CAGR of 7.53% during the forecast period 2023-2033. Rising prevalence of tuberculosis & multidrug-resistant tuberculosis (MDR-TB), growing investment in research & development activities, surge in government initiatives, increasing awareness regarding diagnosis of infectious diseases, rising need for better diagnostic tests & treatment, growing cases of MDR-TB cases among the population, and increasing launch of advanced diagnostic testing by major market players are some of the key factors boosting the market growth.
Increasing launch of advanced diagnostic testing by major market players is predicted to boost the market growth during the forecast period. For instance, in March 2022, SRL Diagnostics has introduced a whole genome sequencing test for tuberculosis, which accelerates the diagnosis of multi-drug resistant tuberculosis and provides a comprehensive resistance profile for 18 different TB drugs.
By Type, Rapid molecular diagnostics was the highest revenue-grossing segment in the global tuberculosis (TB) diagnostics market in 2022 owing to the rising demand for accurate & effective rapid molecular diagnostics for the diagnosis of TB and growing launch of new rapid molecular diagnostic products. For instance, in July 2020, The Foundation for Innovative New Diagnostics (FIND) and Cepheid, Inc. have jointly unveiled the Xpert MTB/XDR test, capable of profiling expanded drug-resistance tuberculosis in under 90 minutes. Additionally, Culture-based diagnostics is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of TB, and growing demand for efficient & technologically advanced diagnostics.
By Diagnostic Test, Nucleic acid testing was the highest revenue-grossing segment in the global tuberculosis (TB) diagnostics market in 2022 owing to the advantages associated with nucleic acid testing such as better accuracy & better results than other microscopy tests, growing adoption of nucleic acid testing for detecting tuberculosis, and increasing regulatory approvals. For instance, in July 2021, F. Hoffmann-La Roche Ltd revealed that the World Health Organization (WHO) has now categorized their products, cobas MTB and cobas MTB-RIF/INH tests, as Nucleic Acid Amplification Tests (NAATs). These testing products are utilized for tuberculosis detection and identifying drug-resistant TB. Additionally, Cytokine Detection Test is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of infectious diseases and growing demand for disease diagnostic testing.
By End User, Clinics & Hospitals was the highest revenue-grossing segment in the global tuberculosis (TB) diagnostics market in 2022 owing to the growing prevalence tuberculosis and increasing demand for tuberculosis diagnosis procedures. Additionally, Diagnostics & research laboratory is predicted to grow at fastest CAGR during the forecast period owing to the surge in number of diagnostic laboratories, growing demand for diagnosis of TB, and increasing products approvals by regulatory bodies. For instance, in March 2021, Hologic Inc has obtained CE marking for its tuberculosis (TB) IGRA test on VIIDAS. The VIDAS TB-IGRA is an automated assay designed to aid in diagnosing Mycobacterium tuberculosis infection.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in prevalence of tuberculosis, growing demand for better diagnostic tests, increasing healthcare investment, rising focus on development of advanced treatments, and surge in launch of new products. For instance, in July 2020, FIND and Cepheid, Inc have introduced the Xpert MTB/XDR test, a novel tool for profiling drug-resistant tuberculosis. This test enables clinicians to promptly prescribe treatment regimens for extensively drug-resistant TB (XDR-TB) and delivers results within 90 minutes. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of infectious diseases, surge in research & development activities, rising demand for better diagnostic tests & treatment, and growing approvals of advanced diagnostic testing by regulatory bodies. For instance, in May 2022, The Drug Controller General of India (DCGI) has approved the market authorization of the Serum Institute's Cy-Tb kit. This kit is intended for individuals aged 18 years and above and can be utilized as a skin test for diagnosing latent tuberculosis.
Increasing launch of advanced diagnostic testing by major market players is predicted to boost the market growth during the forecast period. For instance, in March 2022, SRL Diagnostics has introduced a whole genome sequencing test for tuberculosis, which accelerates the diagnosis of multi-drug resistant tuberculosis and provides a comprehensive resistance profile for 18 different TB drugs.
By Type, Rapid molecular diagnostics was the highest revenue-grossing segment in the global tuberculosis (TB) diagnostics market in 2022 owing to the rising demand for accurate & effective rapid molecular diagnostics for the diagnosis of TB and growing launch of new rapid molecular diagnostic products. For instance, in July 2020, The Foundation for Innovative New Diagnostics (FIND) and Cepheid, Inc. have jointly unveiled the Xpert MTB/XDR test, capable of profiling expanded drug-resistance tuberculosis in under 90 minutes. Additionally, Culture-based diagnostics is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of TB, and growing demand for efficient & technologically advanced diagnostics.
By Diagnostic Test, Nucleic acid testing was the highest revenue-grossing segment in the global tuberculosis (TB) diagnostics market in 2022 owing to the advantages associated with nucleic acid testing such as better accuracy & better results than other microscopy tests, growing adoption of nucleic acid testing for detecting tuberculosis, and increasing regulatory approvals. For instance, in July 2021, F. Hoffmann-La Roche Ltd revealed that the World Health Organization (WHO) has now categorized their products, cobas MTB and cobas MTB-RIF/INH tests, as Nucleic Acid Amplification Tests (NAATs). These testing products are utilized for tuberculosis detection and identifying drug-resistant TB. Additionally, Cytokine Detection Test is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of infectious diseases and growing demand for disease diagnostic testing.
By End User, Clinics & Hospitals was the highest revenue-grossing segment in the global tuberculosis (TB) diagnostics market in 2022 owing to the growing prevalence tuberculosis and increasing demand for tuberculosis diagnosis procedures. Additionally, Diagnostics & research laboratory is predicted to grow at fastest CAGR during the forecast period owing to the surge in number of diagnostic laboratories, growing demand for diagnosis of TB, and increasing products approvals by regulatory bodies. For instance, in March 2021, Hologic Inc has obtained CE marking for its tuberculosis (TB) IGRA test on VIIDAS. The VIDAS TB-IGRA is an automated assay designed to aid in diagnosing Mycobacterium tuberculosis infection.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in prevalence of tuberculosis, growing demand for better diagnostic tests, increasing healthcare investment, rising focus on development of advanced treatments, and surge in launch of new products. For instance, in July 2020, FIND and Cepheid, Inc have introduced the Xpert MTB/XDR test, a novel tool for profiling drug-resistant tuberculosis. This test enables clinicians to promptly prescribe treatment regimens for extensively drug-resistant TB (XDR-TB) and delivers results within 90 minutes. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of infectious diseases, surge in research & development activities, rising demand for better diagnostic tests & treatment, and growing approvals of advanced diagnostic testing by regulatory bodies. For instance, in May 2022, The Drug Controller General of India (DCGI) has approved the market authorization of the Serum Institute's Cy-Tb kit. This kit is intended for individuals aged 18 years and above and can be utilized as a skin test for diagnosing latent tuberculosis.
Segmentation: Tuberculosis (TB) Diagnostics Market Report 2022 - 2033
Tuberculosis (TB) Diagnostics Market Analysis & Forecast by Type 2022 - 2033 (Revenue USD Bn)
- Sputum Smear Microscopy
- Rapid Molecular Diagnostics
- Culture-based Diagnostics
- Others
Tuberculosis (TB) Diagnostics Market Analysis & Forecast by Diagnostic Test 2022 - 2033 (Revenue USD Bn)
- Drug Resistance Test
- Nucleic Acid Testing
- Cytokine Detection Test
- Radiographic Test
- Laboratory Test
- Others
Tuberculosis (TB) Diagnostics Market Analysis & Forecast by End-user 2022 - 2033 (Revenue USD Bn)
- Diagnostics & Research Laboratory
- Clinics & Hospitals
- Other
Tuberculosis (TB) Diagnostics Market Analysis & Forecast by Region 2022 - 2033 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Tuberculosis (TB) Diagnostics Market: Type Estimates & Trend Analysis
8. Tuberculosis (TB) Diagnostics Market: Diagnostic Test Estimates & Trend Analysis
9. Tuberculosis (TB) Diagnostics Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Tuberculosis (TB) Diagnostics Market
12. Europe Global Tuberculosis (TB) Diagnostics Market
13. Asia Pacific Global Tuberculosis (TB) Diagnostics Market
14. Latin America Global Tuberculosis (TB) Diagnostics Market
15. MEA Global Tuberculosis (TB) Diagnostics Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- SRL Diagnostics
- Abbott Laboratories
- F. Hoffmann-La Roche AG
- Hologic Corporation
- FIND
- Becton
- Dickinson and Company
- Cepheid
- Serum Institute of India
- BioMerieux SA
- Qiagen
- Thermo Fisher Scientific Inc.
- AdvaCare Pharma
- Hain Lifescience GmbH
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | August 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 2.84 Billion |
| Forecasted Market Value ( USD | $ 6.3 Billion |
| Compound Annual Growth Rate | 7.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 14 |
